We are live on ! Find out more
Stempoint Capital

Stempoint Capital Portfolio holdings

AUM $560M Turnover 64.34%
1-Year Est. Return 146.87%
This Fund
S&P 500
This Quarter Est. Return
+89.28%
1 Year Est. Return
+146.87%
3 Year Est. Return
+725.67%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$499M
AUM Growth
+$188M
Cap. Flow
+$47.5M
Cap. Flow %
9.53%
Top 10 Hldgs %
50.9%
Holding
101
New
48
Increased
19
Reduced
18
Closed
14
Avg Time Held Equity + Options
0.4 years
Top 10 Avg Time Held Equity + Options
0.5 years
Top 20 Avg Time Held Equity + Options
0.5 years
Avg Time Held Equity only
0.4 years
Top 10 Avg Time Held Equity only
0.5 years
Top 20 Avg Time Held Equity only
0.5 years

Top Buys

Rank Stock Value
1
ROIV icon
Roivant Sciences
ROIV
+$44.5M
2
DNLI icon
Denali Therapeutics
DNLI
+$14.8M
3
BHVN icon
Biohaven
BHVN
+$12.3M
4
WVE icon
Wave Life Sciences
WVE
+$9.8M
5
ARGX icon
argenx
ARGX
+$8.22M

Sector Composition

Rank Sector Weight
1 Healthcare 98.58%
2 Miscellaneous 1.1%
3 Financials 0.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
ROIV icon
1
Roivant Sciences
ROIV
$28B
$63.5M 12.72%
4,197,187
+3,595,406
+597% +$44.5M
2023 Q4
7 quarters
QURE icon
2
uniQure
QURE
$1.46B
$30.5M 6.11%
522,155
-50,460
-9% -$916K
2024 Q4
3 quarters
SRRK icon
3
Scholar Rock
SRRK
$5.5B
$27M 5.42%
726,204
+198,089
+38% +$6.93M
2024 Q4
3 quarters
IMVT icon
4
Immunovant
IMVT
$6.87B
$25.6M 5.13%
1,589,580
+288,720
+22% +$4.67M
2023 Q4
7 quarters
DNLI icon
5
Denali Therapeutics
DNLI
$2.89B
$25.2M 5.05%
1,734,659
+1,026,744
+145% +$14.8M
2024 Q2
5 quarters
SNDX icon
6
Syndax Pharmaceuticals
SNDX
$828M
$21M 4.21%
1,366,205
-1,006,429
-42% -$13.2M
2023 Q4
7 quarters
CNTA
7
DELISTED
Centessa Pharmaceuticals
CNTA
$15.9M 3.18%
655,385
-610,287
-48% -$10.8M
2024 Q3
4 quarters
WVE icon
8
Wave Life Sciences
WVE
$560M
$15.4M 3.09%
2,110,152
+1,209,814
+134% +$9.8M
2024 Q3
4 quarters
BHVN icon
9
Biohaven
BHVN
$2B
$15.3M 3.06%
1,017,311
+842,557
+482% +$12.3M
2023 Q4
7 quarters
CDTX icon
10
DELISTED
Cidara Therapeutics
CDTX
$14.6M 2.92%
152,325
-114,449
-43% -$7.3M
2025 Q2
1 quarter
ABVX icon
11
Abivax
ABVX
$7.19B
$14.1M 2.83%
166,273
+78,525
+89% +$4.81M
2025 Q2
1 quarter
IDYA icon
12
IDEAYA Biosciences
IDYA
$2.65B
$10.1M 2.03%
371,825
+205,940
+124% +$4.98M
2025 Q1
2 quarters
RYTM icon
13
Rhythm Pharmaceuticals
RYTM
$8.08B
$9.23M 1.85%
91,444
-85,308
-48% -$7.92M
2024 Q3
4 quarters
ARGX icon
14
argenx
ARGX
$59.6B
$9.19M 1.84%
+12,465
New +$8.22M
2025 Q3
0 quarters
SRZN icon
15
Surrozen
SRZN
$571M
$9.19M 1.84%
713,463
+26,924
+4% +$282K
2024 Q2
5 quarters
RVMD icon
16
Revolution Medicines
RVMD
$35.2B
$8.66M 1.73%
+185,380
New +$7.26M
2025 Q3
0 quarters
RZLT icon
17
Rezolute
RZLT
$388M
$8.63M 1.73%
917,630
+272,976
+42% +$1.82M
2025 Q2
1 quarter
GHRS icon
18
GH Research
GHRS
$1.25B
$7.8M 1.56%
545,275
+444,449
+441% +$6.22M
2025 Q2
1 quarter
ARQT icon
19
Arcutis Biotherapeutics
ARQT
$3.46B
$7.76M 1.56%
411,893
+206,221
+100% +$3.25M
2023 Q4
7 quarters
VTGN icon
20
VistaGen Therapeutics
VTGN
$8.34M
$7.75M 1.55%
2,488,685
+75,431
+3% +$225K
2023 Q4
7 quarters
XENE icon
21
Xenon Pharmaceuticals
XENE
$3.81B
$7.72M 1.55%
+192,295
New +$6.77M
2025 Q3
0 quarters
ALKS icon
22
Alkermes
ALKS
$7.64B
$7.25M 1.45%
241,637
-109,487
-31% -$3.09M
2024 Q3
4 quarters
CELC icon
23
Celcuity
CELC
$2.84B
$6.75M 1.35%
+136,710
New +$5.47M
2025 Q3
0 quarters
BBIO icon
24
BridgeBio Pharma
BBIO
$15B
$6.62M 1.33%
127,435
+72,805
+133% +$3.55M
2025 Q1
2 quarters
INSM icon
25
Insmed
INSM
$26.7B
$6.25M 1.25%
43,419
-18,159
-29% -$2.22M
2024 Q4
3 quarters

Similar funds

Stempoint Capital's Q3 2025 Portfolio in Review

As of Q3 2025, Stempoint Capital held 101 positions worth $499M, up 60% from $312M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Stempoint Capital deployed $47.5M of net new capital in Q3 2025, opening 48 new positions and adding to 19 existing holdings. Its largest new stake was argenx: 12,465 shares worth $9.19M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Madrigal Pharmaceuticals, an estimated $16.6M trimmed.

  • Stempoint Capital's largest Q3 2025 buy was argenx: 12,465 shares worth $9.19M.
  • Stempoint Capital added most to Roivant Sciences in Q3 2025, an estimated $44.5M increase.
  • Stempoint Capital's biggest Q3 2025 reduction was Madrigal Pharmaceuticals, cutting an estimated $16.6M.
  • Stempoint Capital fully exited Merus in Q3 2025, selling an estimated $14M.
  • Stempoint Capital's ten largest holdings make up 51% of its $499M portfolio in Q3 2025.
  • Stempoint Capital opened 48 new positions and closed 14 in Q3 2025.
  • Stempoint Capital's portfolio value rose 60% quarter-over-quarter to $499M.

Based on Stempoint Capital's 13F filing for Q3 2025, filed 14 Nov 2025.